JP2008514730A5 - - Google Patents

Info

Publication number

JP2008514730A5

JP2008514730A5 JP2007534859A JP2007534859A JP2008514730A5 JP 2008514730 A5 JP2008514730 A5 JP 2008514730A5 JP 2007534859 A JP2007534859 A JP 2007534859A JP 2007534859 A JP2007534859 A JP 2007534859A JP 2008514730 A5 JP2008514730 A5 JP 2008514730A5

Authority

JP

Japan

Prior art keywords

human

antibody

seq

variable region

chain variable

Prior art date

2005-09-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 24
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 16
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 16
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 4
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 206010025323 Lymphomas Diseases 0.000 claims 3
• 206010042971 T-cell lymphoma Diseases 0.000 claims 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 3
• 210000004027 cell Anatomy 0.000 claims 3
• 150000001875 compounds Chemical class 0.000 claims 3
• 210000004881 tumor cell Anatomy 0.000 claims 3
• 208000017604 Hodgkin disease Diseases 0.000 claims 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
• 208000002971 Immunoblastic Lymphadenopathy Diseases 0.000 claims 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
• 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
• FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 claims 2
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 2
• 238000003556 assay Methods 0.000 claims 2
• 108010050213 carbobenzoxy-leucyl-leucyl-norvalinal Proteins 0.000 claims 2
• 230000009089 cytolysis Effects 0.000 claims 2
• 210000004602 germ cell Anatomy 0.000 claims 2
• 230000012010 growth Effects 0.000 claims 2
• 238000001727 in vivo Methods 0.000 claims 2
• 238000012986 modification Methods 0.000 claims 2
• 230000004048 modification Effects 0.000 claims 2
• 239000003207 proteasome inhibitor Substances 0.000 claims 2
• 230000004565 tumor cell growth Effects 0.000 claims 2
• 208000003950 B-cell lymphoma Diseases 0.000 claims 1
• 201000009030 Carcinoma Diseases 0.000 claims 1
• 208000005024 Castleman disease Diseases 0.000 claims 1
• 229930105110 Cyclosporin A Natural products 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
• DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 claims 1
• 229940113306 Ligase inhibitor Drugs 0.000 claims 1
• 102000003945 NF-kappa B Human genes 0.000 claims 1
• 108010057466 NF-kappa B Proteins 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 claims 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
• -1 b-lactone Chemical compound 0.000 claims 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
• 229960001467 bortezomib Drugs 0.000 claims 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
• 229960001265 ciclosporin Drugs 0.000 claims 1
• 239000000701 coagulant Substances 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 229960002706 gusperimus Drugs 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 claims 1
• 239000000436 ligase inhibitor Substances 0.000 claims 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
• 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1